MyFinsight
Home
Blog
About
Contact
Download
Download image
US
$702,554K
Europe
$113,313K
Non USOr Europe
$74,064K
US
$10,166K
Europe
$7,565K
Non USOr Europe
$2,750K
US
$49,091K
Europe
$20,290K
Non USOr Europe
$5,013K
Europe
$24,390K
US
$16,965K
Non USOr Europe
$9,966K
Amvuttra
$889,931K
ONPATTRO
$20,481K
GIVLAARI
$74,394K
OXLUMO
$51,321K
TTR
$910,412K
Rare
$125,715K
Regeneron
Pharmaceuticals Incorporation
$46,336K
Roche
$35,641K
Other Collaborations
$98K
Product
$1,036,127K
Collaborations
$82,075K
Royalty
$48,973K
Total revenues
$1,167,175K
(96.43%↑ Y/Y)
Income from operations
$268,636K
(1386.07%↑ Y/Y)
Total operating costs
and expenses
$898,539K
(55.97%↑ Y/Y)
Income (loss) before
income taxes
$221,653K
(632.87%↑ Y/Y)
Total other expense,
net
-$46,983K
(21.27%↑ Y/Y)
Interest income
$26,598K
(-7.24%↓ Y/Y)
Research and development
$364,866K
(37.62%↑ Y/Y)
Selling, general and
administrative
$322,551K
(34.42%↑ Y/Y)
Cost of goods sold
$207,520K
(195.68%↑ Y/Y)
Cost of
collaborations and royalties
$3,602K
(319.81%↑ Y/Y)
Net income (loss)
$205,991K
(458.38%↑ Y/Y)
Provision for income taxes
$15,662K
(-1.39%↓ Y/Y)
Interest expense
$69,286K
(79.28%↑ Y/Y)
Other (expense)
income, net
-$4,295K
(91.36%↑ Y/Y)
Comprehensive income (loss)
$201,194K
(432.67%↑ Y/Y)
Net other
comprehensive income (gain)
-$4,797K
Defined benefit pension
plans, net of tax
-$89K
(-61.82%↓ Y/Y)
Unrealized (gaines) losss
on marketable...
-$3,652K
(-454.56%↓ Y/Y)
Foreign currency
translation gaines
-$1,234K
Back
Back
Income Statement
ALNYLAM PHARMACEUTICALS, INC. (ALNY)
ALNYLAM PHARMACEUTICALS, INC. (ALNY)
source: myfinsight.com